Arcadia Biosciences
RKDA
23 hedge funds and large institutions have $3.17M invested in Arcadia Biosciences in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 3 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 2
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
66% more call options, than puts
Call options by funds: $2.39M | Put options by funds: $1.44M
21% more funds holding
Funds holding: 19 → 23 (+4)
12% more capital invested
Capital invested by funds: $2.82M → $3.17M (+$347K)
0.07% less ownership
Funds ownership: 0.21% → 0.14% (-0.07%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$360K |
| 2 |
Millennium Management
New York
|
+$273K |
| 3 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
+$220K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$189K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$125K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$759K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$324K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$144K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$7.97K |
RKDA Hedge Fund Activity: Q1 2021 in Review
23 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q1 2021, worth a combined $3.17M — up 12% from $2.82M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new RKDA positions and 3 closed out — a net gain of 4 holders — while 10 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $360K. The largest seller was Ardsley Advisory Partners, exiting entirely with an estimated $759K sold.
- 23 institutional investors held Arcadia Biosciences (RKDA) as of Q1 2021, up from 19 in Q4 2020.
- Funds reported $3.17M of Arcadia Biosciences stock for Q1 2021, up 12% quarter-over-quarter.
- 7 funds opened new Arcadia Biosciences positions in Q1 2021 and 3 closed out, a net change of +4 holders.
- The largest Arcadia Biosciences buyer in Q1 2021 was Vanguard Group, an estimated $360K added.
- The largest Arcadia Biosciences seller in Q1 2021 was Ardsley Advisory Partners, an estimated $759K sold.
Based on aggregated 13F filings for Q1 2021.